Press Releases

Investors

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Arrowhead Pharmaceuticals Announces Precautionary Measures to Mitigate Effects of Novel Coronavirus (COVID-19) Spread
PASADENA, Calif. --(BUSINESS WIRE)-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced precautionary measures the company is taking to help protect the health and safety of its employees, partners, and the healthcare workers and patients involved in ongoing clinical studies of
View HTML
Toggle Summary Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Marketplace Rule 5635(c)(4)
PASADENA, Calif. --(BUSINESS WIRE)-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that as an inducement to entering into employment with the Company, on March 11, 2020 , the Compensation Committee of the Board of Directors approved "inducement" grants to 31 new employees under Rule
View HTML
Toggle Summary Arrowhead Pharmaceuticals Initiates Phase 1/2 Study of ARO-HSD in Normal Healthy Volunteers and Patients with NASH or Suspected NASH
PASADENA, Calif. --(BUSINESS WIRE)-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has dosed the first patients in AROHSD1001, a Phase 1/2 clinical study of ARO-HSD, the company’s investigational RNA interference (RNAi) therapeutic being developed as a treatment for patients
View HTML
Toggle Summary Arrowhead Pharmaceuticals to Participate in Upcoming March 2020 Conferences
PASADENA, Calif. --(BUSINESS WIRE)-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events: Barclays Global Healthcare Conference – Miami , March 10-12, 2020 March 11 , 11:15 a.m.
View HTML
Toggle Summary Arrowhead Pharmaceuticals Reports Fiscal 2020 First Quarter Results
Conference Call and Webcast Today, Feb. 5 at 4:30 p.m. EDT PASADENA, Calif. --(BUSINESS WIRE)--Feb. 5, 2020-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced financial results for its fiscal first quarter ended December 31, 2019 . The company is hosting a conference call at 4:30 p.m.
View HTML
Toggle Summary Arrowhead Reports Interim Clinical Data on Cardiometabolic Candidates ARO-APOC3 and ARO-ANG3
- Multiple-dose data across various patient populations show marked improvement in multiple lipid parameters - Company targets initiation of pivotal studies in 2020 PASADENA, Calif. --(BUSINESS WIRE)--Feb. 5, 2020-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today reported promising interim
View HTML
Toggle Summary Arrowhead Pharmaceuticals to Webcast Fiscal 2020 First Quarter Results
PASADENA, Calif. --(BUSINESS WIRE)--Jan. 22, 2020-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on February 5, 2020 , at 4:30 p.m. EST to discuss its financial results for the fiscal first quarter ended December 31, 2019 .
View HTML
Toggle Summary Arrowhead Pharmaceuticals Appoints James Hassard as Chief Commercial Officer
PASADENA, Calif. --(BUSINESS WIRE)--Jan. 6, 2020-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced the appointment of James Hassard to the newly-created position of chief commercial officer. Mr. Hassard will be responsible for driving commercial strategy and building the team and
View HTML
Toggle Summary Arrowhead Pharmaceuticals Doses First Patient in AROAAT2002 Open Label Phase 2 Study of ARO-AAT for Treatment of Alpha-1 Liver Disease
PASADENA, Calif. --(BUSINESS WIRE)--Dec. 20, 2019-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has dosed the first patient in AROAAT2002, an open-label Phase 2 clinical study of ARO-AAT, the company’s second generation investigational RNA interference (RNAi) therapeutic
View HTML
Toggle Summary Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Marketplace Rule 5635(c)(4)
PASADENA, Calif. --(BUSINESS WIRE)--Dec. 16, 2019-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that as an inducement to entering into employment with the Company, on December 6, 2019 , the Compensation Committee of the Board of Directors approved "inducement" grants to 21 new
View HTML